Cargando…
Can the Addition of Maintenance Electroconvulsive Therapy to Pharmacotherapy Improve Relapse Prevention in Severe Major Depressive Disorder? A Randomized Controlled Trial
Few systematic evaluations have been performed of the efficacy of electroconvulsive therapy (ECT) as a relapse prevention strategy in major depressive disorder (MDD). This is a single-blind, multicenter, randomized controlled trial to compare the efficacy and tolerability of pharmacotherapy plus mai...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534103/ https://www.ncbi.nlm.nih.gov/pubmed/34679404 http://dx.doi.org/10.3390/brainsci11101340 |
_version_ | 1784587474460213248 |
---|---|
author | Martínez-Amorós, Erika Cardoner, Narcís Gálvez, Verònica de Arriba-Arnau, Aida Soria, Virginia Palao, Diego J. Menchón, José M. Urretavizcaya, Mikel |
author_facet | Martínez-Amorós, Erika Cardoner, Narcís Gálvez, Verònica de Arriba-Arnau, Aida Soria, Virginia Palao, Diego J. Menchón, José M. Urretavizcaya, Mikel |
author_sort | Martínez-Amorós, Erika |
collection | PubMed |
description | Few systematic evaluations have been performed of the efficacy of electroconvulsive therapy (ECT) as a relapse prevention strategy in major depressive disorder (MDD). This is a single-blind, multicenter, randomized controlled trial to compare the efficacy and tolerability of pharmacotherapy plus maintenance ECT (M-Pharm/ECT) versus pharmacotherapy alone (M-Pharm) in the prevention of MDD relapse. Subjects with MDD who had remitted with bilateral acute ECT (n = 37) were randomly assigned to receive M-Pharm/ECT (n = 19, 14 treatments) or M-Pharm (n = 18) for nine months. The subjects were followed up for 15 months. The main outcome was relapse of depression, defined as a score of 18 or more on the Hamilton Depression Rating Scale. At nine months, 35% of the subjects treated with M-Pharm/ECT relapsed as compared with 61% of the patients treated with M-Pharm. No statistically significant differences between groups were indicated by either Kaplan–Meier or Cox proportional hazards regression analyses. The subjects without psychotic features were at higher risk of relapse. There were no statistically significant differences in the MMSE scores of the two groups at the end of the study. Further studies are needed to better define the indications for M-ECT in order to improve its efficacy as a relapse prevention strategy. |
format | Online Article Text |
id | pubmed-8534103 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85341032021-10-23 Can the Addition of Maintenance Electroconvulsive Therapy to Pharmacotherapy Improve Relapse Prevention in Severe Major Depressive Disorder? A Randomized Controlled Trial Martínez-Amorós, Erika Cardoner, Narcís Gálvez, Verònica de Arriba-Arnau, Aida Soria, Virginia Palao, Diego J. Menchón, José M. Urretavizcaya, Mikel Brain Sci Article Few systematic evaluations have been performed of the efficacy of electroconvulsive therapy (ECT) as a relapse prevention strategy in major depressive disorder (MDD). This is a single-blind, multicenter, randomized controlled trial to compare the efficacy and tolerability of pharmacotherapy plus maintenance ECT (M-Pharm/ECT) versus pharmacotherapy alone (M-Pharm) in the prevention of MDD relapse. Subjects with MDD who had remitted with bilateral acute ECT (n = 37) were randomly assigned to receive M-Pharm/ECT (n = 19, 14 treatments) or M-Pharm (n = 18) for nine months. The subjects were followed up for 15 months. The main outcome was relapse of depression, defined as a score of 18 or more on the Hamilton Depression Rating Scale. At nine months, 35% of the subjects treated with M-Pharm/ECT relapsed as compared with 61% of the patients treated with M-Pharm. No statistically significant differences between groups were indicated by either Kaplan–Meier or Cox proportional hazards regression analyses. The subjects without psychotic features were at higher risk of relapse. There were no statistically significant differences in the MMSE scores of the two groups at the end of the study. Further studies are needed to better define the indications for M-ECT in order to improve its efficacy as a relapse prevention strategy. MDPI 2021-10-11 /pmc/articles/PMC8534103/ /pubmed/34679404 http://dx.doi.org/10.3390/brainsci11101340 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Martínez-Amorós, Erika Cardoner, Narcís Gálvez, Verònica de Arriba-Arnau, Aida Soria, Virginia Palao, Diego J. Menchón, José M. Urretavizcaya, Mikel Can the Addition of Maintenance Electroconvulsive Therapy to Pharmacotherapy Improve Relapse Prevention in Severe Major Depressive Disorder? A Randomized Controlled Trial |
title | Can the Addition of Maintenance Electroconvulsive Therapy to Pharmacotherapy Improve Relapse Prevention in Severe Major Depressive Disorder? A Randomized Controlled Trial |
title_full | Can the Addition of Maintenance Electroconvulsive Therapy to Pharmacotherapy Improve Relapse Prevention in Severe Major Depressive Disorder? A Randomized Controlled Trial |
title_fullStr | Can the Addition of Maintenance Electroconvulsive Therapy to Pharmacotherapy Improve Relapse Prevention in Severe Major Depressive Disorder? A Randomized Controlled Trial |
title_full_unstemmed | Can the Addition of Maintenance Electroconvulsive Therapy to Pharmacotherapy Improve Relapse Prevention in Severe Major Depressive Disorder? A Randomized Controlled Trial |
title_short | Can the Addition of Maintenance Electroconvulsive Therapy to Pharmacotherapy Improve Relapse Prevention in Severe Major Depressive Disorder? A Randomized Controlled Trial |
title_sort | can the addition of maintenance electroconvulsive therapy to pharmacotherapy improve relapse prevention in severe major depressive disorder? a randomized controlled trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534103/ https://www.ncbi.nlm.nih.gov/pubmed/34679404 http://dx.doi.org/10.3390/brainsci11101340 |
work_keys_str_mv | AT martinezamoroserika cantheadditionofmaintenanceelectroconvulsivetherapytopharmacotherapyimproverelapsepreventioninseveremajordepressivedisorderarandomizedcontrolledtrial AT cardonernarcis cantheadditionofmaintenanceelectroconvulsivetherapytopharmacotherapyimproverelapsepreventioninseveremajordepressivedisorderarandomizedcontrolledtrial AT galvezveronica cantheadditionofmaintenanceelectroconvulsivetherapytopharmacotherapyimproverelapsepreventioninseveremajordepressivedisorderarandomizedcontrolledtrial AT dearribaarnauaida cantheadditionofmaintenanceelectroconvulsivetherapytopharmacotherapyimproverelapsepreventioninseveremajordepressivedisorderarandomizedcontrolledtrial AT soriavirginia cantheadditionofmaintenanceelectroconvulsivetherapytopharmacotherapyimproverelapsepreventioninseveremajordepressivedisorderarandomizedcontrolledtrial AT palaodiegoj cantheadditionofmaintenanceelectroconvulsivetherapytopharmacotherapyimproverelapsepreventioninseveremajordepressivedisorderarandomizedcontrolledtrial AT menchonjosem cantheadditionofmaintenanceelectroconvulsivetherapytopharmacotherapyimproverelapsepreventioninseveremajordepressivedisorderarandomizedcontrolledtrial AT urretavizcayamikel cantheadditionofmaintenanceelectroconvulsivetherapytopharmacotherapyimproverelapsepreventioninseveremajordepressivedisorderarandomizedcontrolledtrial |